Real-World Utilization of Immune Globulin Subcutaneous 16.5% in Treatment-Naïve Primary Immunodeficient Patients

Presented at ACAAI 2022

Authors:
Jeffrey W. Langford, MD, AE-C
Richard F. Herrscher, MD, FACAAI
Dawn N. Kim-Romo, PharmD, PhD
Lucinda J. Van Anglen, PharmD